OPK


Opko Health Rolls Out Multiplex COVID-19, Influenza A/B Test

Opko Health’s subsidiary BioReference Laboratories has launched a new multiplex test that will aid healthcare providers, clinics and health systems in the diagnosis …

Opko’s BioReference Lab Begins Covid-19 Testing At NYC Schools

BioReference Laboratories, a wholly-owned subsidiary of Opko Health, has commenced its COVID-19 testing program for New York City public schools. The testing will …

3 “Strong Buy” Healthcare Stocks Under $5 That Could Go Boom

Since 2019, the healthcare sector has been bracing for the wild ride that would be the election year. However, according to some Street …

Opko Launches Phase 2 Trial Of Covid Treatment Rayaldee; Street Bullish

Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market …

3 Compelling Penny Stocks With at Least 50% Upside Potential

Dark clouds are looming over Wall Street, and the storm only appears to be intensifying. The market was dealt another blow on Wednesday …

4 Notable Analyst Calls in the Biotech Space: Cymabay (CBAY), Opko (OPK), Chimerix (CMRX), Intec (NTEC)

It has been an ugly day for the markets in the past few days.  The biotech sector has been particularly hard hit.

Opko Health Inc. (OPK) Kidney Disease Franchise Keeps This Bull’s Conviction Despite 3Q Earnings Misstep

Louise Chen: Even with less-than-impressive sales for the quarter, OPK stock still poses long-term value.

Opko Health Inc. (OPK) Announces 3Q:17 Financial Results; Shares Tumble

Opko Health Inc. (NASDAQ:OPK) reports operating and financial results for the three months ended September 30, 2017.

Opko Health Inc. (OPK) Opens Wider Window in CINV Market Thanks to Varubi Approval, Cheers Cantor

Louise Chen notes that under OPK’s agreement with Tesaro, the approval of Varubi IV is a huge win.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts